2020 Archives - Page 3 of 3 - ImmunityBio

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

Jul 7, 2020 | Head & Neck

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

May 20, 2020 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses

May 6, 2020 | COVID-19

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.

Apr 16, 2020 | Merkel Cell Carcinoma, Non-Small Cell Lung Cancer

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.

Oct 8, 2019 | Colorectal Cancer

Next Entries »